According to a post, Y Combinator has launched YC Bio, a fund focused on backing early-stage life science companies that are still in the lab phase.
The first area the the fund is going to focus on is healthspan and age-related disease.
The companies will go through the regular YC batch, but, instead of the standard deal for YC companies (which is $120k invested for 7% ownership), YC will offer companies any amount between $500k and $1m for 10-20% ownership, scaling linearly.
Companies will also receive free lab space, a number of other special deals for YC bio companies, and access to a wide range of experts.
Email: [email protected]
FinSMEs
14/01/2018